How Agendia’s breast cancer assays are testing the limits of race-based clinical assumptions
Race matters in care access, but tumor biology may drive response. Agendia’s FLEX data sharpen the breast cancer equity debate.
Medical Devices & Diagnostics
Pharma & Biotech
Can Assertio win market traction with convenience-led G-CSF dosing schedules?
Can same-day dosing of Rolvedon reduce burden in breast cancer care? Explore new trial data, regulatory risks, and clinical impact in this detailed analysis.
Medical Devices & Diagnostics
Can personalized ctDNA finally solve the risk stratification gap in therapy-resistant early breast cancer?
New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.
Medical Devices & Diagnostics
How AidaBreast’s multi-omic insights may reduce overtreatment in breast cancer care
Prelude Corporation has announced the first independent validation of AidaBreast, a multi-omic diagnostic test developed to predict both locoregional recurrence risk and individualized radiation therapy benefit in early-stage hormone receptor-positive, HER2-negative invasive breast cancer. The study, conducted at Royal Melbourne Hospital and presented at the San Antonio Breast Cancer Symposium 2025, evaluated over 400 women